COPD in Respiratory Care: A Clinical Overview (2026)

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation that is not fully reversible. It develops gradually over time and is most commonly associated with long-term exposure to cigarette smoke, environmental pollutants, or occupational irritants.

COPD is a major cause of morbidity and mortality worldwide and represents a significant burden on patients, families, and healthcare systems. For respiratory therapists, COPD is encountered across the entire continuum of care, from outpatient management to critical care support.

What is COPD?

Chronic obstructive pulmonary disease (COPD) is a chronic and progressive lung disorder characterized by persistent airflow limitation that is not fully reversible. It develops over time due to long-term exposure to harmful particles or gases, most commonly cigarette smoke, but also environmental pollutants and occupational irritants.

COPD includes two primary conditions: emphysema, which involves destruction of the alveoli and loss of elastic recoil, and chronic bronchitis, which is defined by chronic inflammation of the airways and excessive mucus production. These structural changes lead to symptoms such as chronic cough, sputum production, wheezing, and shortness of breath, especially during exertion.

As the disease progresses, gas exchange becomes impaired, and patients may develop hypoxemia or hypercapnia. Early diagnosis and appropriate management are essential to slow progression and reduce complications.

Diagnostic Criteria

From a functional standpoint, COPD is defined by spirometry. The hallmark finding is a reduced ratio of forced expiratory volume in one second to forced vital capacity, or FEV1 over FVC. A post-bronchodilator FEV1 over FVC ratio of less than 0.70 confirms persistent airflow limitation.

The degree of airflow obstruction is then classified based on the percentage of predicted FEV1. This classification helps guide treatment decisions and risk assessment.

While spirometry confirms the diagnosis, COPD is fundamentally a clinical disease. Patients typically present with chronic cough, sputum production, dyspnea on exertion, or a history of exposure to noxious particles such as tobacco smoke.

Pathophysiology of COPD

COPD is not a single pathologic process. It involves structural changes in the airways, destruction of lung parenchyma, and chronic inflammation. These changes lead to airflow limitation, air trapping, and impaired gas exchange.

Small Airway Disease

In COPD, the small airways, typically less than 2 millimeters in diameter, become inflamed and narrowed. Chronic exposure to irritants leads to:

• Airway wall thickening
• Mucus gland enlargement
• Increased goblet cells
• Excess mucus production

The lumen of the airway becomes narrowed due to inflammation, fibrosis, and mucus plugging. This increases airway resistance, especially during expiration.

Because expiration is normally a passive process that depends on elastic recoil, any reduction in airway caliber disproportionately affects expiratory flow. This leads to prolonged expiration and air trapping.

Emphysematous Destruction

Emphysema is defined anatomically as abnormal, permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls and loss of elastic recoil.

Destruction of alveolar septa reduces the surface area available for gas exchange. Loss of elastin decreases the elastic recoil pressure that normally keeps small airways open during expiration. As a result, small airways collapse prematurely during exhalation, trapping air in the lungs.

This leads to:

• Increased residual volume
• Increased total lung capacity
• Hyperinflation
• Flattening of the diaphragm

Note: Hyperinflation places the respiratory muscles at a mechanical disadvantage. The diaphragm becomes shortened and less efficient, increasing the work of breathing.

Ventilation-Perfusion Mismatch

As structural damage progresses, ventilation and perfusion become mismatched. Areas of the lung may be ventilated but poorly perfused, or perfused but poorly ventilated.

In emphysema, destruction of alveolar walls and capillary beds contributes to increased dead space ventilation. In chronic bronchitis, mucus plugging and airway narrowing contribute to low ventilation relative to perfusion, leading to hypoxemia.

Note: Over time, chronic hypoxemia may lead to pulmonary vasoconstriction, pulmonary hypertension, and cor pulmonale.

Gas Exchange Abnormalities

In early COPD, arterial carbon dioxide levels are often normal. As airflow obstruction becomes severe, alveolar hypoventilation may occur, resulting in hypercapnia.

Many patients with stable, advanced COPD exhibit compensated respiratory acidosis. The kidneys retain bicarbonate to buffer the chronically elevated PaCO2. During acute exacerbations, compensation may be overwhelmed, leading to uncompensated respiratory acidosis.

Emphysema vs. Chronic Bronchitis

Although most patients have features of both processes, it is important to understand the distinguishing characteristics of emphysema and chronic bronchitis.

Emphysema

Emphysema primarily affects the alveoli and distal airspaces. The dominant feature is destruction of lung parenchyma.

Common characteristics include:

• Severe dyspnea
• Minimal sputum production
• Hyperinflation and barrel-shaped chest
• Diminished breath sounds
• Hyperresonant percussion

Patients with predominant emphysema often maintain relatively better oxygenation in early stages because ventilation is preserved, even though surface area is reduced. They may develop significant dyspnea due to increased work of breathing.

Pulmonary function testing typically reveals:

• Reduced FEV1
• Reduced FEV1 over FVC ratio
• Increased residual volume and total lung capacity
• Decreased diffusing capacity for carbon monoxide

Note: Lung compliance is increased due to loss of elastic tissue.

Chronic Bronchitis

Chronic bronchitis is defined clinically as a productive cough lasting at least three months per year for two consecutive years, after other causes of chronic cough have been excluded.

The primary problem is airway inflammation and mucus hypersecretion.

Common characteristics include:

• Chronic productive cough
• Frequent respiratory infections
• Wheezing and rhonchi
• Cyanosis in advanced disease

In chronic bronchitis, gas exchange abnormalities may occur earlier due to ventilation-perfusion mismatch from mucus plugging.

Pulmonary function testing shows:

• Reduced FEV1
• Reduced FEV1 over FVC ratio
• Increased residual volume

Note: The diffusing capacity is often normal because the alveolar structure may remain intact.

Risk Factors and Etiology

COPD is strongly associated with environmental and genetic factors.

Cigarette Smoking

Cigarette smoking is the leading cause of COPD in developed countries. Long-term inhalation of tobacco smoke triggers chronic inflammation, oxidative stress, and protease-mediated tissue destruction.

Not all smokers develop COPD, which suggests a component of individual susceptibility. However, smoking accounts for the majority of COPD-related deaths. Smoking cessation slows the rate of decline in lung function. Even after diagnosis, quitting smoking remains one of the most effective interventions to alter disease progression.

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency is a genetic disorder that can lead to early-onset emphysema. Alpha-1 antitrypsin is a protease inhibitor that protects lung tissue from neutrophil elastase. When levels are low, elastase activity may go unchecked, resulting in accelerated destruction of alveolar walls.

This condition should be suspected in patients with:

• Early onset emphysema
• Minimal smoking history
• Family history of lung or liver disease
• Emphysema predominant in the lung bases

Note: Respiratory therapists should be aware of this condition, especially when interpreting pulmonary function tests in younger patients with airflow obstruction.

Environmental and Occupational Exposures

In addition to smoking, other risk factors include:

• Biomass fuel exposure
• Air pollution
• Occupational dust and chemical exposure
• Secondhand smoke

Note: In many parts of the world, indoor cooking with biomass fuels in poorly ventilated environments contributes significantly to disease burden.

Clinical Presentation

COPD develops gradually. Patients often attribute early symptoms to aging or deconditioning.

Common symptoms include:

• Chronic cough
• Sputum production
• Dyspnea on exertion
• Wheezing
• Chest tightness

Note: Dyspnea typically progresses slowly and becomes more prominent in later stages.

Physical Examination Findings

Early findings may be subtle. As disease advances, clinicians may observe:

• Prolonged expiratory phase
• Use of accessory muscles
• Increased anteroposterior diameter of the chest
• Decreased breath sounds
• Wheezing or rhonchi

In advanced cases, signs of right-sided heart failure may develop, including peripheral edema. Digital clubbing is not typical of COPD alone. Its presence should prompt evaluation for other conditions such as lung cancer or interstitial lung disease.

Why COPD Matters in Respiratory Care

COPD is a core diagnosis in respiratory care because it affects large patient populations, creates frequent contact points across care settings, and often requires long-term monitoring and education.

It is also a leading driver of acute respiratory admissions due to exacerbations. In the outpatient setting, respiratory care focuses on assessment, medication technique, oxygen evaluation, pulmonary rehabilitation support, and prevention.

In the inpatient setting, respiratory therapists manage oxygen and ventilation strategies, administer bronchodilators, support secretion clearance, assist with diagnostic testing, and help guide escalation of care during decompensation.

COPD also intersects with many other conditions seen by respiratory therapists, including pneumonia, heart failure, pulmonary hypertension, sleep-disordered breathing, and lung cancer. Patients often carry multiple comorbidities, making assessment and treatment decisions more complex.

Note: In many organizations, COPD care is tied to quality metrics, readmissions, and discharge planning, which increases the importance of standardized respiratory care processes.

COPD Across the Continuum of Care

Respiratory therapists commonly see COPD in several settings:

• Pulmonary function laboratories, where obstruction is identified and bronchodilator responsiveness is assessed
• Emergency departments, where acute exacerbations present with distress, hypoxemia, and hypercapnia
• Medical wards, where oxygen titration, bronchodilator delivery, and monitoring occur
• Intensive care units, where ventilatory support may be necessary
• Outpatient clinics and home care, where oxygen therapy, education, and adherence issues are central

Note: Because COPD is chronic, the same patient may move repeatedly across these settings, which makes continuity, documentation, and patient education critical. Respiratory therapists often become the bridge between diagnostic data, bedside physiology, and practical interventions that patients can follow after discharge.

Relevance to Respiratory Therapists

Respiratory therapists play a direct role in diagnosing, stabilizing, and optimizing patients with COPD. In many settings, therapists are among the first clinicians to recognize worsening respiratory status, rising work of breathing, or signs of ventilatory failure.

COPD also requires strong patient education and device coaching, which aligns closely with the respiratory therapist scope of practice.

Assessment and Recognition of Deterioration

A central RT contribution is to identify when a patient with COPD is compensated and stable versus when they are failing. COPD patients can appear deceptively stable until they tire, retain carbon dioxide, or develop acute-on-chronic respiratory failure.

Key bedside findings that suggest deterioration include:

• Rising respiratory rate with increased accessory muscle use
• Worsening wheeze, diminished air entry, or markedly prolonged expiratory time
• New or worsening hypoxemia despite increased oxygen
• Altered mental status, agitation, or somnolence
• Inability to speak full sentences
• Hemodynamic instability in severe cases

Note: Respiratory therapists also monitor for signs of hyperinflation and air trapping, such as difficulty triggering a ventilator, increasing intrinsic PEEP, or patient discomfort during exhalation.

Pulmonary Function Testing and Interpretation

Pulmonary function testing is foundational to COPD. Respiratory therapists often perform spirometry and help ensure test quality. Beyond reporting numbers, RTs translate results into meaningful clinical context.

Important spirometric patterns include:

• Obstruction confirmed by reduced post-bronchodilator FEV1/FVC
• Severity staging based on FEV1 percent predicted
• Limited bronchodilator reversibility that still may be present in many patients

Note: Respiratory therapists should also recognize that some patients exhibit features consistent with overlap between asthma and COPD, such as prominent bronchodilator response, symptom variability, or eosinophilia, which can influence therapy choices. Differentiation is not always clean, and clinical history matters.

Oxygen Therapy and Safe Titration

Oxygen is frequently required in COPD, but it must be titrated thoughtfully. The practical goal is to correct hypoxemia while minimizing the risk of worsening hypercapnia in susceptible patients.

For many COPD patients, an SpO2 range of 88% to 92% is a common target, especially during exacerbations or when hypercapnia risk is known or suspected. This range aims to provide adequate oxygenation without excessive oxygen delivery.

Therapists contribute by:

• Selecting appropriate delivery devices
• Adjusting flow rates and FiO2 based on response
• Monitoring for signs of carbon dioxide retention
• Reassessing frequently, especially after changes in oxygen settings

Not every COPD patient retains carbon dioxide when given oxygen, but some do. Several mechanisms are discussed in clinical practice, including changes in ventilation-perfusion matching and the Haldane effect.

Note: Regardless of the mechanism, the bedside priority is to titrate oxygen to a safe target and monitor ABGs or transcutaneous or end-tidal trends when available and appropriate.

Aerosolized Bronchodilator Delivery and Technique

Bronchodilators are used to relieve bronchospasm and reduce symptoms. RTs are responsible for selecting delivery methods and ensuring correct technique, which has a major impact on effectiveness.

In stable disease, patients may use short-acting bronchodilators as needed and long-acting bronchodilators for maintenance. During exacerbations, short-acting beta-2 agonists are commonly used, sometimes alongside anticholinergics.

RT responsibilities include:

• Choosing nebulizer versus MDI with spacer based on patient ability and severity
• Coaching inhaler technique and confirming patient understanding
• Monitoring response and adverse effects such as tachycardia or tremor
• Avoiding unnecessarily frequent dosing that increases side effects without added benefit

Note: Even experienced patients often misuse inhalers. Repeated assessment and education are essential. Small technique improvements can produce meaningful symptom changes and reduce unnecessary escalation.

Acute Exacerbation of COPD

Acute exacerbations are episodes of worsening respiratory symptoms beyond normal day-to-day variation. They are often triggered by infection or environmental exposure, but other causes of dyspnea can mimic an exacerbation.

The respiratory therapist’s role includes assessment, initial treatment support, monitoring response, and helping determine whether the patient can remain on the ward, needs noninvasive ventilation, or requires intubation.

Common Clinical Features

An acute exacerbation may include:

• Increased dyspnea
• Increased cough
• Increased sputum volume
• Change in sputum color or character
• Increased wheezing or chest tightness
• Increased fatigue and decreased activity tolerance

Note: Severity can vary. A mild exacerbation may respond to increased bronchodilator use. A severe exacerbation may include ventilatory failure, acidemia, or altered mental status.

Initial Evaluation and RT Priorities

Respiratory therapists help guide evaluation and monitoring through:

• Continuous pulse oximetry and trending respiratory rate and effort
• ABG sampling when indicated, particularly if SpO2 is low, hypercapnia is suspected, or mental status changes are present
• Assessment of airway secretions, cough effectiveness, and need for airway clearance support
• Coordination of bronchodilator therapy and oxygen titration
• Early recognition of failure to respond

Not every dyspneic COPD patient is having a pure COPD exacerbation. Common alternative or coexisting problems include:

• Pneumonia
• Heart failure and pulmonary edema
• Pulmonary embolism
• Pneumothorax
• Arrhythmias
• Medication nonadherence or device misuse

Note: Chest imaging and basic laboratory assessment are often required to identify these issues. In some cases, a BNP level or cardiac evaluation is used to help differentiate heart failure from COPD-related dyspnea.

Noninvasive Ventilation in COPD Exacerbation

Noninvasive ventilation is often preferred for COPD exacerbations with hypercapnic respiratory failure, provided there are no contraindications. It can reduce the work of breathing, improve ventilation, correct acidemia, and reduce intubation rates when used appropriately.

NIV is commonly considered when a patient has:

• Acute or acute-on-chronic hypercapnia
• Respiratory acidosis
• Increased work of breathing with fatigue
• Persistent hypoxemia despite oxygen therapy, especially when hypercapnia is also present

Contraindications can include inability to protect the airway, severe agitation, copious secretions with poor clearance, facial trauma, or high aspiration risk. NIV success depends heavily on setup, coaching, and troubleshooting, which are areas where RT expertise is central.

Key responsibilities include:

• Selecting the appropriate interface and ensuring a good seal
• Setting initial pressures and adjusting based on clinical response and ABG trends
• Monitoring for air leaks, patient-ventilator asynchrony, gastric distention, and skin breakdown
• Coaching the patient through anxiety and mask intolerance
• Ensuring adequate expiratory time to reduce air trapping

Note: A practical bedside goal is to improve pH and reduce respiratory distress, rather than to normalize PaCO2 immediately. Many COPD patients have chronically elevated PaCO2, so the focus is on correcting dangerous acidemia and reducing fatigue.

When Invasive Mechanical Ventilation Is Needed

Despite optimal medical management and NIV, some patients progress to respiratory failure requiring intubation and invasive ventilation.

Indications may include:

• Worsening acidemia or rising PaCO2 with clinical decline
• Severe hypoxemia not correctable with noninvasive support
• Inability to protect the airway
• Persistent or worsening altered mental status
• Hemodynamic instability or impending arrest

Once intubated, COPD patients require careful ventilator management to avoid dynamic hyperinflation and barotrauma. That includes allowing sufficient expiratory time, avoiding excessive respiratory rates, and monitoring for auto-PEEP.

Close attention to patient comfort and synchrony is also important because agitation can worsen air trapping and increase pressures.

Stages of COPD

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD severity primarily based on the degree of airflow limitation measured by spirometry. After confirming persistent airflow obstruction with a post-bronchodilator FEV1/FVC ratio less than 0.70, severity is graded according to the percent predicted FEV1.

These stages help guide prognosis, treatment intensity, and monitoring strategies.

GOLD 1: Mild (FEV1 ≥ 80% Predicted)

In GOLD 1, airflow limitation is present but relatively mild. Patients may have chronic cough and sputum production, but many are asymptomatic or attribute mild dyspnea to aging or deconditioning.

Spirometry shows:

• FEV1 ≥ 80% of predicted
• FEV1/FVC < 0.70

At this stage, smoking cessation and risk factor modification are critical. Short-acting bronchodilators may be used as needed for symptom relief.

GOLD 2: Moderate (FEV1 50%–79% Predicted)

GOLD 2 is characterized by worsening airflow limitation and more noticeable symptoms. Dyspnea typically develops with exertion, and patients may begin limiting physical activity.

Spirometry shows:

• FEV1 between 50% and 79% of predicted
• FEV1/FVC < 0.70

Long-acting bronchodilators are often introduced at this stage. Pulmonary rehabilitation may also be recommended to improve exercise tolerance and quality of life.

GOLD 3: Severe (FEV1 30%–49% Predicted)

In GOLD 3, airflow obstruction is severe, and exacerbations become more frequent. Dyspnea significantly limits daily activities, and patients may experience recurrent hospitalizations.

Spirometry shows:

• FEV1 between 30% and 49% of predicted
• FEV1/FVC < 0.70

Combination inhaled therapies are commonly used. Clinicians may also evaluate the need for long-term oxygen therapy in patients with resting hypoxemia.

GOLD 4: Very Severe (FEV1 < 30% Predicted)

GOLD 4 represents very severe airflow limitation and advanced disease. Patients often have marked dyspnea at rest or with minimal exertion and may develop chronic respiratory failure.

Spirometry shows:

• FEV1 < 30% of predicted
• FEV1/FVC < 0.70

Complications such as hypercapnia, pulmonary hypertension, and cor pulmonale are more common. Management may include long-term oxygen therapy, noninvasive ventilation in selected patients, and evaluation for advanced therapies such as lung transplantation in appropriate candidates.

Symptom and Exacerbation Risk Assessment

In addition to spirometric staging, GOLD also emphasizes assessment of symptom burden and exacerbation history. Tools such as the COPD Assessment Test (CAT) and the Modified Medical Research Council (mMRC) dyspnea scale are used to quantify symptoms. Exacerbation frequency helps determine future risk and influences treatment decisions.

Note: Spirometric grading and clinical assessment provide a more comprehensive framework for managing COPD and tailoring therapy to individual patient needs.

Hospital Discharge and Prevention of Readmissions

Respiratory therapists contribute to safe discharge by confirming stable oxygen needs, ensuring proper medication delivery technique, and reinforcing self-management planning.

Many readmissions occur due to incomplete understanding of medications, poor inhaler technique, lack of follow-up, ongoing smoking, or delayed recognition of worsening symptoms.

Education and Self-Management Skills

Effective education is specific and practical. It should include:

• How and when to use rescue versus maintenance inhalers
• How to recognize early signs of exacerbation
• When to seek urgent medical care
• Proper device cleaning and maintenance
• Strategies for energy conservation and breathing control

Note: Patients benefit from repetition and demonstration. A teach-back method helps confirm understanding.

Pulmonary Rehabilitation and Functional Improvement

Pulmonary rehabilitation improves symptoms and quality of life and can reduce healthcare utilization. Respiratory therapists support rehabilitation by:

• Reinforcing exercise tolerance goals
• Teaching breathing strategies, including paced breathing and pursed-lip breathing
• Supporting airway clearance techniques when indicated
• Encouraging adherence and follow-up

Note: Rehabilitation also provides a structured setting for education and early detection of clinical decline.

Smoking Cessation Support

Smoking cessation is the most impactful intervention for slowing disease progression in many patients. RTs often have repeated contact with patients and can reinforce cessation efforts by:

• Identifying readiness to quit
• Encouraging use of counseling and pharmacologic support when appropriate
• Reinforcing the relationship between smoking and symptoms
• Helping the patient connect cessation goals to functional outcomes, such as walking tolerance or reduced dyspnea

Long-Term Management of Stable COPD

Stable COPD management focuses on reducing symptoms, improving functional status, preventing exacerbations, and slowing progression. Because COPD is heterogeneous, treatment is individualized based on symptom burden, exacerbation history, spirometric impairment, comorbidities, and patient goals.

Respiratory therapists contribute by confirming physiologic needs, optimizing device use, reinforcing action plans, and monitoring response over time.

Pharmacologic Therapy Overview

Maintenance medications in COPD primarily target bronchomotor tone and airway inflammation. They do not reverse the underlying structural disease, but they can reduce symptoms and lower exacerbation risk.

Bronchodilators

Bronchodilators are first-line therapy in most patients because airflow limitation in COPD often includes a reversible component, even when obstruction is not fully reversible.

Key principles include:

• Short-acting bronchodilators are used for immediate symptom relief.
• Long-acting bronchodilators are used for maintenance and prevention of symptoms.
• Dual bronchodilation may be used in patients with persistent symptoms.

Note: RTs support bronchodilator therapy by ensuring the patient can correctly use the prescribed device and by evaluating whether delivery method changes may improve adherence and symptom control.

Inhaled Corticosteroids

Inhaled corticosteroids are not universally indicated in COPD. They are typically considered when patients have recurrent exacerbations, specific inflammatory features, or overlap characteristics that suggest a higher likelihood of steroid responsiveness.

Important considerations include:

• Inhaled corticosteroids can reduce exacerbation frequency in selected patients.
• They may increase pneumonia risk in some patients.
• They are often used in combination with a long-acting bronchodilator rather than as monotherapy.

Note: RTs can help identify patterns of frequent exacerbations and communicate these patterns to the care team, while also reinforcing monitoring for adverse effects.

Methylxanthines and Other Options

Methylxanthines such as theophylline are used less commonly due to limited additional benefit and potential toxicity. When used, monitoring and adherence are important because therapeutic ranges are narrow.

Other therapies aimed at reducing exacerbations may be considered in selected patients, including phosphodiesterase-4 inhibitors or chronic macrolide therapy. These decisions are typically made by the prescribing clinician, but RTs often help with monitoring tolerance, adherence, and symptom trends.

Nonpharmacologic Therapy

Nonpharmacologic strategies are central in COPD because they target functional limitation, reduce exacerbation risk, and address long-term outcomes that medications alone cannot.

Pulmonary Rehabilitation

Pulmonary rehabilitation improves dyspnea perception, exercise tolerance, and quality of life. It does not restore lung function, but it improves how the patient functions with the lung function they have.

Common components include:

• Lower and upper extremity exercise training
• Breathing retraining and pacing strategies
• Education on medications and self-management
• Psychosocial support and coping strategies

Note: Respiratory therapists reinforce skills taught in rehabilitation, particularly breathing pattern control, secretion management when needed, and safe use of oxygen during activity.

Vaccination and Infection Prevention

Infections are common triggers for COPD exacerbations and can lead to prolonged decline. Preventive measures include annual influenza vaccination and pneumococcal vaccination according to current recommendations.

RTs reinforce prevention through practical counseling, including avoidance of sick contacts when possible, early evaluation of worsening symptoms, and adherence to prescribed therapies.

Smoking Cessation

Smoking cessation remains the most effective way to slow disease progression in many COPD patients. RTs support cessation by revisiting the topic frequently, providing nonjudgmental reinforcement, and encouraging evidence-based resources, including counseling and pharmacotherapy when appropriate.

Long-Term Oxygen Therapy and Reassessment

Oxygen is prescribed to correct hypoxemia, and in patients with severe resting hypoxemia, long-term oxygen therapy can improve survival. Oxygen is not a dyspnea treatment by itself unless dyspnea is driven by hypoxemia, so accurate assessment is essential.

Identifying Appropriate Candidates

Candidates are typically identified through resting oximetry and arterial blood gas testing, often after optimization of bronchodilator therapy. RTs are central in ensuring assessments are performed correctly and repeated when appropriate.

Key RT responsibilities include:

• Selecting the right test condition, including rest, exertion, and sleep when indicated
• Ensuring adequate time on room air before evaluation when clinically safe
• Documenting flow requirements and device performance
• Educating on safe oxygen use, portability, and adherence

Reassessment After Exacerbations

Patients started on oxygen during an acute exacerbation should be reassessed after recovery to determine whether oxygen remains necessary. RT-led follow-up and communication can prevent unnecessary long-term oxygen use and can identify those who still require therapy.

Chronic Hypercapnia and Home NIV

Some patients with advanced COPD develop chronic hypercapnic ventilatory failure. In selected patients, long-term noninvasive ventilation at home may reduce exacerbations and improve outcomes. Evidence varies based on patient selection, timing, and ventilation strategy.

RTs play a role by:

• Educating patients and caregivers on interface care and troubleshooting
• Monitoring adherence and comfort
• Identifying excessive leaks or poor synchrony
• Reinforcing follow-up testing when ordered

Note: Home NIV is not appropriate for every COPD patient. It is typically considered when hypercapnia persists despite optimized medical therapy.

Critical Care Considerations in COPD

COPD patients admitted to the ICU often present with acute-on-chronic respiratory failure. Treatment priorities are to correct hypoxemia, manage hypercapnia and acidemia, reduce work of breathing, and treat triggers such as infection.

Mechanical Ventilation Goals

Mechanical ventilation in COPD is not only about achieving gas exchange. It must also address dynamic hyperinflation and the risk of ventilator-induced complications.

Key goals include:

• Adequate oxygenation with the lowest effective FiO2
• Adequate ventilation with permissive hypercapnia when appropriate
• Sufficient expiratory time to reduce air trapping
• Avoiding excessive minute ventilation demands that increase auto-PEEP

Note: Respiratory therapists play a major role in monitoring waveforms, assessing auto-PEEP, optimizing synchrony, and communicating physiologic trends to the care team.

Managing Dynamic Hyperinflation and Auto-PEEP

Dynamic hyperinflation occurs when the patient does not fully exhale before the next breath begins. This increases end-expiratory lung volume and creates intrinsic PEEP, which can impair venous return, raise intrathoracic pressures, and increase work of breathing.

RT strategies include:

• Reducing respiratory rate when possible
• Adjusting inspiratory time to allow longer expiration
• Monitoring flow-time curves for incomplete exhalation
• Using bronchodilators and secretion management to reduce resistance
• Considering external PEEP carefully to improve triggering in select cases

Note: The specifics of ventilator adjustments depend on patient effort, lung mechanics, and clinical goals. Trend-based decisions are essential.

Weaning and Extubation Planning

COPD patients may be difficult to wean due to ongoing airflow obstruction, respiratory muscle fatigue, and persistent hypercapnia. Successful weaning often requires attention to:

• Bronchodilator optimization
• Secretion management and cough effectiveness
• Nutritional status and electrolyte balance
• Avoiding excessive sedation
• Coordinating spontaneous breathing trials with close monitoring

Note: In selected patients, transitioning from invasive ventilation to NIV after extubation can support ventilation and reduce reintubation risk. RTs contribute by identifying appropriate candidates and supporting NIV initiation and monitoring.

COPD Practice Questions

1. What is chronic obstructive pulmonary disease (COPD)?
COPD is a chronic, progressive lung disease characterized by persistent airflow limitation that is not fully reversible and is associated with an abnormal inflammatory response to noxious particles or gases.

2. What is the leading cause of COPD worldwide?
Cigarette smoking

3. Which conditions are classified under COPD?
Chronic bronchitis and emphysema.

4. How is airflow limitation in COPD described?
Airflow obstruction that is persistent and not fully reversible, typically confirmed by spirometry.

5. What are the most common symptoms of COPD?
Chronic dyspnea, cough, and sputum production.

6. How is chronic bronchitis clinically defined?
Productive cough for at least 3 months per year for 2 consecutive years, after excluding other causes.

7. What is the primary structural change seen in emphysema?
Destruction of alveolar walls leading to enlarged airspaces and reduced elastic recoil.

8. What is the gold standard test for diagnosing COPD?
Spirometry

9. What spirometric finding confirms airflow obstruction in COPD?
A post-bronchodilator FEV1/FVC ratio less than 0.70.

10. What additional tests may support COPD evaluation?
Arterial blood gas analysis, chest radiograph, CT scan, and alpha-1 antitrypsin testing when indicated.

11. What are the primary management goals in COPD?
Reduce symptoms, improve exercise tolerance, prevent exacerbations, and improve quality of life.

12. What is the first-line pharmacologic therapy for stable COPD?
Inhaled bronchodilators

13. Which bronchodilator classes are commonly used in COPD?
Beta2-agonists and anticholinergics.

14. Why are inhaled corticosteroids used in some COPD patients?
To reduce airway inflammation and exacerbation frequency in patients with frequent exacerbations.

15. When are systemic corticosteroids indicated in COPD?
During acute exacerbations to reduce inflammation and improve lung function.

16. What are common causes of chronic bronchitis?
Long-term smoking and chronic exposure to air pollutants.

17. What breath sounds are often heard in advanced chronic bronchitis?
Wheezes, rhonchi, and coarse crackles.

18. What arterial blood gas pattern is typical in advanced COPD?
Chronic compensated respiratory acidosis with hypoxemia.

19. What is a key difference between asthma and COPD?
Asthma is typically reversible with bronchodilators, whereas COPD airflow limitation is not fully reversible.

20. What is the strongest risk factor for developing COPD?
Cumulative tobacco exposure measured in pack-years.

21. What is hypercapnia?
An elevated arterial carbon dioxide level (PaCO2).

22. When should palliative or hospice care be considered in COPD?
In advanced disease with severe functional limitation and frequent exacerbations despite optimal therapy.

23. How is COPD severity commonly staged?
Using spirometric classification based on FEV1 percent predicted.

24. What nonpharmacologic therapy improves outcomes in COPD?
Pulmonary rehabilitation

25. What are common triggers of COPD exacerbations?
Respiratory infections, air pollution, and environmental irritants.

26. What is an advance directive?
A legal document outlining a patient’s healthcare preferences if they become unable to communicate.

27. What inflammatory characteristic is associated with COPD?
Chronic airway inflammation with neutrophilic predominance.

28. How does smoking increase the risk of death from COPD?
Smokers have a significantly higher mortality rate compared with nonsmokers due to progressive lung damage.

29. What are bronchodilators?
Medications that relax airway smooth muscle to improve airflow.

30. What structural change in COPD contributes to air trapping?
Loss of elastic recoil leading to premature airway closure during exhalation.

31. What cardiovascular complication can develop as a result of advanced COPD?
Cor pulmonale, which is right-sided heart failure caused by chronic pulmonary hypertension.

32. Is digital clubbing a common finding in uncomplicated COPD?
No, digital clubbing is not typical in COPD and should prompt evaluation for other conditions such as lung cancer or bronchiectasis.

33. Which COPD phenotype is historically described as a “pink puffer”?
Emphysema

34. Which COPD phenotype is historically described as a “blue bloater”?
Chronic bronchitis

35. Which COPD subtype is more commonly associated with chronic productive cough?
Chronic bronchitis

36. Which COPD subtype is more commonly associated with severe dyspnea and minimal sputum production?
Emphysema

37. At what age is COPD most commonly diagnosed?
Typically in individuals older than 40 years with significant smoking history.

38. Which COPD phenotype is more likely to present with peripheral edema due to right-sided heart failure?
Chronic bronchitis

39. Which COPD subtype may present with diminished or “quiet” breath sounds due to hyperinflation?
Emphysema

40. What are the key pathophysiologic features of chronic bronchitis?
Chronic airway inflammation, mucous gland enlargement, excessive mucus production, and airflow obstruction.

41. Which disease is more prevalent worldwide, asthma or COPD?
Asthma is more prevalent, but COPD has a higher mortality rate.

42. What physical exam findings are commonly seen in advanced COPD?
Barrel chest, prolonged expiratory phase, use of accessory muscles, and pursed-lip breathing.

43. What are the three hallmark symptoms of COPD?
Chronic cough, sputum production, and progressive dyspnea.

44. What are common complications of advanced COPD?
Pulmonary hypertension, cor pulmonale, recurrent infections, polycythemia, and respiratory failure.

45. Who should be screened with spirometry for possible COPD?
Individuals over 40 years old with a history of smoking and respiratory symptoms.

46. What nonpharmacologic intervention is most effective in slowing COPD progression?
Smoking cessation

47. Is COPD curable?
No, COPD is not curable, but it is treatable and manageable.

48. Can COPD be prevented?
Yes, many cases are preventable by avoiding tobacco smoke and environmental pollutants.

49. Is COPD mortality higher in men or women?
COPD mortality rates are now similar or slightly higher in women in many countries.

50. What is alpha-1 antitrypsin deficiency?
A genetic disorder that results in low levels of alpha-1 antitrypsin, increasing the risk of early-onset emphysema and liver disease.

51. What is the second most common cause of COPD in the United States after smoking?
Alpha-1 antitrypsin (AAT) deficiency.

52. What percentage of COPD cases is attributed to alpha-1 antitrypsin deficiency?
Approximately 1% to 3% of cases.

53. How is alpha-1 antitrypsin deficiency inherited?
It is inherited in an autosomal codominant pattern.

54. What serum AAT level is considered below the protective threshold for emphysema risk?
Less than 11 μmol/L (approximately 57 mg/dL).

55. Which pathophysiologic theory of emphysema is supported by alpha-1 antitrypsin deficiency?
The protease–antiprotease imbalance hypothesis.

56. Which enzyme is primarily responsible for alveolar wall destruction in emphysema when not adequately inhibited?
Neutrophil elastase

57. What environmental exposure is a major global risk factor for COPD besides cigarette smoking?
Biomass fuel exposure in poorly ventilated indoor environments.

58. What imaging pattern may suggest alpha-1 antitrypsin deficiency–related emphysema?
Basilar-predominant emphysema on CT scan.

59. At approximately what FEV1 level does chronic carbon dioxide retention commonly develop in COPD?
When FEV1 falls below about 1 liter or 30% of predicted.

60. What arterial blood gas pattern is typical in stable, advanced COPD?
Compensated respiratory acidosis with hypoxemia.

61. What ABG pattern is seen during an acute COPD exacerbation with ventilatory failure?
Acute or acute-on-chronic respiratory acidosis with elevated PaCO2 and acidemia.

62. What oxygen saturation target is recommended for most COPD patients during an acute exacerbation?
An SpO2 between 88% and 92%.

63. Why is excessive oxygen administration avoided in COPD exacerbations?
High oxygen levels may worsen hypercapnia in susceptible patients.

64. Why is routine spirometry not recommended during an acute COPD exacerbation?
It provides limited clinical value and may worsen respiratory distress.

65. What is a major indication for noninvasive ventilation (NIV) in COPD exacerbations?
Acute hypercapnic respiratory failure with a pH less than 7.35.

66. What ventilator adjustment helps reduce dynamic hyperinflation in intubated COPD patients?
Prolonging expiratory time by lowering respiratory rate and increasing inspiratory flow.

67. What is auto-PEEP in COPD?
Intrinsic positive end-expiratory pressure caused by incomplete exhalation and air trapping.

68. What is a common infectious trigger of COPD exacerbations?
Acute bacterial or viral lower respiratory tract infections.

69. When are antibiotics indicated in COPD exacerbations?
When patients have increased dyspnea, sputum volume, and sputum purulence, or require mechanical ventilation.

70. What is the typical recommended dose and duration of oral prednisone for acute COPD exacerbation?
Prednisone 40 mg daily for 5 days in most cases.

71. What is the primary goal of pulmonary rehabilitation in COPD?
To improve functional capacity, reduce dyspnea, and enhance quality of life.

72. Does pulmonary rehabilitation significantly improve FEV1 in COPD?
No, it improves symptoms and exercise tolerance but does not significantly change lung function.

73. What is cor pulmonale in the context of COPD?
Right ventricular failure resulting from chronic pulmonary hypertension due to lung disease.

74. What classic chest x-ray findings are associated with emphysema?
Hyperinflation, flattened diaphragms, and increased retrosternal airspace.

75. What is asthma-COPD overlap (ACO)?
A condition characterized by persistent airflow limitation with features of both asthma and COPD.

76. What percentage of cigarette smokers are estimated to be susceptible to accelerated lung function decline leading to COPD?
Approximately 15% to 20% of smokers develop clinically significant COPD.

77. Which landmark clinical trial demonstrated that smoking cessation slows the rate of FEV1 decline?
The Lung Health Study.

78. What major structural protein is destroyed in emphysema?
Elastin within the alveolar walls.

79. How does emphysema affect lung compliance?
Lung compliance increases due to loss of elastic recoil.

80. How does chronic hypoxemia contribute to pulmonary hypertension in COPD?
Sustained hypoxic pulmonary vasoconstriction increases pulmonary vascular resistance.

81. What is Hoover sign in severe COPD?
Paradoxical inward movement of the lower rib cage during inspiration due to diaphragmatic flattening.

82. What thoracic configuration is commonly observed in advanced emphysema?
An increased anteroposterior diameter, often described as a barrel chest.

83. What is asterixis, and when might it occur in COPD?
A flapping tremor of the hands that may be seen in severe hypercapnia.

84. What is the recommended first-line bronchodilator during an acute COPD exacerbation?
A short-acting beta2-agonist (SABA), such as albuterol.

85. What is a commonly used nebulized albuterol dose during COPD exacerbations?
2.5 mg every 1 to 4 hours as needed.

86. Do doses of albuterol above standard recommendations significantly improve outcomes in COPD exacerbations?
No, higher doses generally increase side effects without meaningful additional bronchodilation.

87. Which laboratory test may help differentiate a COPD exacerbation from acute heart failure?
Brain natriuretic peptide (BNP) level.

88. Why is spirometry generally avoided during severe COPD exacerbations?
It does not change acute management and may worsen respiratory distress.

89. What is the primary purpose of noninvasive ventilation (NIV) in acute COPD exacerbation?
To reduce work of breathing and correct respiratory acidosis.

90. When increasing ventilation on NIV, which parameter should be adjusted?
Inspiratory positive airway pressure (IPAP).

91. How can clinicians maintain pressure support if auto-PEEP develops but ventilation is adequate?
Increase both IPAP and EPAP proportionally to preserve the pressure gradient.

92. What inspiratory-to-expiratory (I:E) ratio is preferred for mechanically ventilated COPD patients?
An I:E ratio of 1:3 or longer to allow adequate exhalation.

93. What is the most common underlying diagnosis in patients undergoing lung transplantation worldwide?
Chronic obstructive pulmonary disease.

94. What FEV1 value may prompt consideration for lung transplantation evaluation in advanced COPD?
Less than 20% to 25% of predicted in carefully selected patients.

95. What is lung volume reduction surgery (LVRS)?
A surgical procedure that removes diseased emphysematous lung tissue to improve elastic recoil and respiratory mechanics.

96. Which pattern of emphysema shows the greatest benefit from LVRS?
Upper-lobe–predominant heterogeneous emphysema.

97. What is the approximate five-year survival rate after lung transplantation for COPD?
Approximately 50% to 60%.

98. What is intravenous augmentation therapy used for in COPD?
Treatment of severe alpha-1 antitrypsin deficiency to slow emphysema progression.

99. What is a major limitation of alpha-1 antitrypsin augmentation therapy?
It is costly and requires lifelong intravenous infusions.

100. What is the primary objective of COPD disease management programs?
To reduce exacerbations, improve quality of life, and decrease hospital admissions.

Final Thoughts

COPD is a chronic disease defined by persistent airflow limitation and a variable mix of small airway inflammation and emphysematous destruction. Because patients can be stable for long periods and then deteriorate quickly during exacerbations, consistent assessment and monitoring are essential.

Respiratory therapists contribute across the continuum by performing and interpreting pulmonary function tests, optimizing inhaled medication delivery, titrating oxygen, and supporting ventilatory assistance when needed.

Long-term outcomes are shaped by prevention, smoking cessation support, rehabilitation, and timely escalation of care when respiratory failure develops.